Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
Image
Cannabis News
October 1, 2024
SciSparc receives FDA approval for a Phase IIb trial of a cannabinoid based treatment for Tourette Syndrome. SciSparc Ltd., a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company
Cannabis Technology News
by Rolando Garcia
Read More: Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome
Comments are closed, but trackbacks and pingbacks are open.